Program
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726
Its studies are mostly in Carcinoma, Hepatocellular, led by Compass Therapeutics.
Furthest: phase 1, since Feb 12, 20261 company-led study, 1 open or runningNext primary completion: Apr 1, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Compass Therapeutics | 11 open or running | phase 1since Feb 12, 2026 | Feb 12, 2026 | Apr 1, 2028phase 1 · NCT07419841 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 12, 2026First study: phase 1 study in Carcinoma, HepatocellularFirst studyNCT07419841 · 70 planned · United States
Ahead
- Apr 1, 2028Primary completion: phase 1 study in Carcinoma, HepatocellularNCT07419841
TargetBeta
“A tetravalent bispecific antibody consisting of a Fc-silenced, immunoglobulin G1 (IgG1) antibody targeting human vascular endothelial growth factor A (VEGF-A), and single chain variable fragment (scFv) targeting the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1;”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| tivunatamig | Pfizer | phase 3 | 15 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010 | Merck | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039Arule | Minghui Pharmaceutical | phase 2 | 3 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rule | wigen-biomedicine-technology-shanghai-co-ltd | phase 2 | 2 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07419841Carcinoma, Hepatocellular · United States | 1 | Recruiting | Apr 1, 2028 | 70 |
How it is read
Names in the registry
- “CTX-10726”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.